Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
P 1 (3)
P 3 (1)

Trial Status

Active Not Recruiting3
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04013542Phase 1Active Not RecruitingPrimary

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

NCT02201992Phase 3Active Not RecruitingPrimary

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT03707938Phase 1Active Not Recruiting

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT04005144Phase 1TerminatedPrimary

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Showing all 4 trials

Research Network

Activity Timeline